Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Ray-Coquard, I.; Leary, A.; Pignata, S.; Cropet, C.; González-Martín, A.; Marth, C.; Nagao, S.; Vergote, I.; Colombo, N.; Mäenpää, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Guerra Alia, E. M.; Bogner, G.; Yoshida, H.; Lefeuvre-Plesse, C.; Buderath, P.; Mosconi, A. M.; Lortholary, A.; Burges, A.; Medioni, J.; El-Balat, A.; Rodrigues, M.; Park-Simon, T. -W.; Dubot, C.; Denschlag, D.; You, B.; Pujade-Lauraine, E.; Harter, P.